The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRIT Capital Partners Regulatory News (RCP)

Share Price Information for RIT Capital Partners (RCP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,950.00
Bid: 1,946.00
Ask: 1,950.00
Change: 30.00 (1.56%)
Spread: 4.00 (0.206%)
Open: 1,922.00
High: 1,950.00
Low: 1,922.00
Prev. Close: 1,920.00
RCP Live PriceLast checked at -
RIT Capital Partners is an Investment Trust

To invest in a widely diversified, international portfolio across a range of asset classes, both quoted and unquoted; to allocate part of the portfolio to exceptional managers in order to ensure access to the best external talent available.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

7 Feb 2024 07:00

RNS Number : 2433C
RIT Capital Partners PLC
07 February 2024
 

RIT Capital Partners PLC (LEI: P31Q1NLTW35JJGHA4667)

 

7 February 2024

 

December 2023 Preliminary Unaudited Net Asset Value

 

The preliminary, unaudited, diluted net asset value (NAV) of RIT Capital Partners plc as at 31 December 2023 (with debt at fair value) was 2,426p per £1 ordinary share (30 November 2023 NAV: 2,377p).

 

2023 Performance Highlights

 

Despite consensus at the start of 2023 indicating an impending recession and the probability of interest rate hikes, global equity markets posted strong returns throughout the year. Concerns about central banks struggling with inflation management, potentially leading to economic downturns, subsided as economic growth remained favourable, and inflation pressures eased. This set off a rally in asset prices, particularly in the final two months of the year, resulting in significant year-on-year increases in indices. The S&P 500 closed the year with a gain of +26.3%, the MSCI ACWI (50% £) saw an increase of +18.4%, and the FTSE 250 rose +8.0%. However, the rally was driven by a small number of stocks, especially in the US, where the majority of the S&P 500's annual return came from a select group of technology stocks known as the 'Magnificent Seven'.

 

Our NAV return was positive for the year, rising by 3.2%, with strong contributions from our quoted equities book and our uncorrelated strategies holdings. Private Investments and sterling's strength were the primary detractors. During the year, we maintained our moderate net equity exposure of 39%, reflecting our defensive positioning for this book.

 

Our aims and objectives remain long term. Including 2023, our NAV per share total return over the last 10 years was almost 109%. Since inception, RIT has now participated in 74% of monthly market increases but only 41% of market declines, with our NAV compounding at 10.5% per annum and generating a share price total return of 10.6% per annum.

 

Key performance drivers in 2023 were:

 

·

Quoted equities performed strongly during the year. The book delivered healthy double-digit returns, outpacing the MSCI ACWI equal-weighted index for the year.

The book benefitted from strong returns in our direct stock holdings, including Builders FirstSource which we exited earlier in the year, achieving a +67% return on our investment in just under a year.

Other significant contributors included our holdings in Japan and healthcare-focused managers, both of which delivered strong returns for the year.

The key detractor during the year was China, where disappointment with the speed and strength of the post-Covid recovery, a lack of fiscal stimulus and global outflows exerted downward pressure on shares.

·

Private investments detracted modestly from NAV during the year. Our direct private investments showed resilience and were roughly flat over the year. Our private fund investments fell modestly, partly due to the customary lagged receipt of valuations for the final quarter of 2022.

During the year, we successfully exited three direct positions via secondary sales. This includes Infinity, which was sold in early 2023 at an uplift to our prior carrying value, with final cash proceeds from the sale received in early February this year.

We also successfully completed sales of the majority of two other positions within our top 10 holdings at their carrying values, achieving returns of 2.0x and 3.9x our original investments.

In line with our usual practice, the NAV reflects the six-monthly revaluation of our direct holdings to 31 December 2023 by our independent Valuation Committee. Of our private funds, 99% are valued as at 30 September (with the remainder at 30 June).

·

Our uncorrelated strategies book also performed well, delivering solid performance in line with our expectations for this book.

Performance during the period was led by credit funds, which posted healthy double-digit returns for the year.

We also saw positive contributions from our holding in California Carbon Credits, as well as our holdings in gold.

·

Underlying asset returns from our diversified global exposure were impacted by currency movements given sterling was the best performing currency in the G7. Our active hedging efforts helped to mitigate the impact of currency fluctuations.

·

Discounts across the investment trust industry widened considerably in 2023, and our discount was no exception, ending the year at -22%. During the year, we completed the largest buyback in our history and one of the largest in the industry, repurchasing £162 million or approximately 8.6 million shares during the year. This buyback programme was accretive to shareholders, adding 1.2% to the NAV per share.

·

In 2023, the Company also paid a total dividend of 38p per share, paid in two equal instalments in April and October, an increase over the prior year.

 

 

As is customary at this point in our year-end process, the preliminary NAV and associated performance numbers are estimates, and subject to potential adjustment and audit. Full details will be included in the 2023 Annual Report & Accounts, which is expected to be published by early March.

 

 

For more information:

J. Rothschild Capital Management (Manager):

T: 020 7647 8565

E: investorrelations@ritcap.co.uk

 

Numis (Joint broker):

David Benda

T: 020 7260 1000

 

JP Morgan Cazenove (Joint broker):

William Simmonds

T: 020 3493 8000

 

Brunswick Group LLP (Media enquiries):

Nick Cosgrove, Tom Burns

T: 020 7404 5959

E: RIT@BrunswickGroup.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVVQLFBZLLBBBF
Date   Source Headline
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSNet Asset Value(s)
4th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20242:27 pmRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
20th Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20245:22 pmRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSNet Asset Value(s)
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20244:56 pmRNSDirector/PDMR Shareholding
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSFinal Results
5th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 202410:32 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20245:13 pmRNSDirectorate Change
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20241:31 pmRNSCompany Announcement
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSNet Asset Value(s)
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSNet Asset Value(s)
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20241:49 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.